H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Personalis to $10 from $13 and keeps a Buy rating on the shares following the Q4 results. The analyst tempered growth expectations for the company’s biopharma revenues.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PSNL:
- Personalis reports Q4 EPS (67c), consensus (64c)
- Personalis upgraded to Buy at Needham on cost reductions, biopharma potential
- Personalis upgraded to Buy from Hold at Needham
- Personalis, Moderna announce new agreement to leverage NeXT Platform
- Personalis raises FY22 revenue view to about $65M, consensus $63.6M
